AIM
VKTX icon

Axiom Investment Management’s Viking Therapeutics VKTX Stock Holding History

Axiom Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13,000
Closed -$104K – 149
2019
Q4 		$104K Hold
13,000
– – 0.15% 111
2019
Q3 		$89K Hold
13,000
– – 0.07% 176
2019
Q2 		$108K Hold
13,000
– – 0.02% 384
2019
Q1 		$129K Buy
+13,000
New +$109K 0.02% 367

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Axiom Investment Management's VKTX Position: Q1 2020 in Review

Axiom Investment Management sold out of Viking Therapeutics (VKTX) in Q1 2020, closing a stake of 13,000 shares — an estimated $104K sold.

Axiom Investment Management first reported a position in VKTX in Q1 2019 and held it in 4 quarters. The position peaked at $129K in Q1 2019. 137 funds tracked by Wall St. Rank hold VKTX as of Q1 2020.

  • Axiom Investment Management reported no remaining Viking Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Axiom Investment Management sold 13,000 Viking Therapeutics shares in Q1 2020, an estimated $104K.
  • Axiom Investment Management first reported a position in Viking Therapeutics in Q1 2019 and held it in 4 quarters.
  • Axiom Investment Management's Viking Therapeutics position peaked at $129K in Q1 2019.
  • 137 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2020.

Based on Axiom Investment Management's 13F filing for Q1 2020, filed 16 Mar 2021.